7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adr

Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

546177, C07D21520, C07D21522, C07D215227

Patent

active

055764371

ABSTRACT:
The subject invention involves methods of treating nasal congestion comprising administration, to a human or lower animal in need of such treatment of a safe and effective amount of a compound having the following structure: ##STR1## wherein: (a) R is unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl; and

REFERENCES:
patent: 3890319 (1975-06-01), Danielewicz et al.
patent: 4029792 (1977-06-01), Danielewicz et al.
patent: 4036976 (1977-07-01), Neumann
patent: 4217356 (1980-08-01), Neumann
patent: 4398028 (1983-08-01), Neumann
patent: 5021416 (1991-06-01), Gluchowski
patent: 5091528 (1992-02-01), Gluchowski
patent: 5180721 (1993-01-01), Burke
patent: 5231096 (1993-07-01), Gluchowski et al.
patent: 5281591 (1994-01-01), Burke
Cambridge, D., "UK-14,304, A Potent and Selective .alpha..sub.2 -Agonist for the Characterization of .alpha.-Adrenoceptor Subtypes", European Journal of Pharmacology, vol. 72, pp. 413-415 (1981).
Chapleo, C. B., J. C. Doxey, P. L. Myers, M. Myers, C. F. C. Smith and M. R. Stillings, "Effect of 1,4-Dioxanyl Substitution on the Adrenergic Activity of some Standard .alpha.-Adrenoreceptor Agents", European Journal of Medicinal Chemistry, vol. 24, pp. 619-622 (1989).
Chapleo, C. B., R. C. M. Butler, D. C. England, P. L. Myers, A. G. Roach, C. F. C. Smith, M. R. Stillings and I. F. Tulloch, "Heteroaromatic Analogues of the .alpha..sub.2 -Adrenoreceptor Partial Agonist Clondine", J. Med. Chem., vol. 32, pp. 1627-1630 (1989).
Clare, K. A., M. C. Scrutton and N. T. Thompson, "Effects of .alpha..sub.2 -Adrenoreceptor Agonists and of Related Compounds on Aggregation of, and on Adenylate Cyclose Activity in, Human Platelets", Br. J. Pharmacl, vol. 82, pp. 467-476 (1984).
Timmermans, P. B. M. W. M. and P. A. van Zwieten, ".alpha..sub.2 -Adrenoceptor Agonists and Antagonists", Drugs of the Future, vol., 9, No. 1, pp. 41-55 (Jan. 1984).
Timmermans, P. B. M. W. M. A. T. Chiu and M. J. M. C. Thoolen, "12,1 .alpha..sub.2 -Adrenergic Receptors", Comprehensive Medicinal Chemistry, vol. 3, Membranes & Receptors, pp. 133-185 (1990).
Timmermans, P. B. M. W. M. A. de Jonge, M. J. M. C. Thoolen, B. Wilffert, H. Batink and P. A. van Zwieten, "Quantitative Relationships between" .alpha..sub.2 -Adrenergic Activity and Binding Affinity of .alpha..sub.2 -Adrenoceptor Agonists and Antagonists, J. Med. Chem., vol. 27, pp. 495-503 (1984).
Megens, A. A. H. P., J. E. Leysen, F. H. L. Awouters and C. J. E. Niemegeers, "Ruther Validation of In Vivo and In Vitro Pharmacological Procedures for Assessing the" .alpha..sub.2/ .alpha..sub.1 -Selectivity of Test Compounds: (2) .alpha.-Adrenoceptor Agonists, European Journal of Pharmacology, vol. 129, pp. 57-64 (1986).
Van Meel, J. C. A., A. de Jonge, P. B. M. W. M. Timmermans and P. A. van Zwieten, "Selectivity of Some Alpha Adrenoceptor Agonists for Peripheral Alpha-1 and Alpha-2 Adrenoceptors in the Normotensive Rat", The Journal of Pharmacology and Experimental Therapeutics, vol. 219, pp. 760-767 (1981).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adr does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adr, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adr will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-542023

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.